Geron Corp. Company Profile (NASDAQ:GERN)

Analyst Ratings

Consensus Ratings for Geron Corp. (NASDAQ:GERN) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.80 (159.05% upside)

Analysts' Ratings History for Geron Corp. (NASDAQ:GERN)
Show:
DateFirmActionRatingPrice TargetActions
5/8/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$5.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Geron Corp. (NASDAQ:GERN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q116($0.06)($0.06)$0.26 million$0.74 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.05)($0.05)$0.32 million$0.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.12$0.17$17.87 million$35.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q2 15($0.06)($0.05)$0.40 million$0.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.06)($0.06)$0.32 million$0.54 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q4$0.17($0.06)$35.35 million$0.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.06)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.06)($0.06)$0.22 million$0.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.06)($0.06)$0.35 million$0.47 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.06)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.07)($0.07)$0.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.06)($0.06)$0.49 million$0.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.07)($0.07)$0.50 million$0.11 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013($0.08)($0.09)$0.71 million$0.77 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2013Q4 2012($0.14)($0.12)$0.50 million$0.69 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012Q312($0.14)($0.13)$0.38 million$0.64 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012($0.15)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.18)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.18)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.18)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2011($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011($0.19)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Geron Corp. (NASDAQ:GERN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Geron Corp. (NASDAQ:GERN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Geron Corp. (NASDAQ:GERN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/29/2015Olivia Kyusuk BloomCFOSell2,380$3.84$9,139.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Thomas HofstaetterDirectorSell70,000$4.10$287,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Melissa Kelly BehrsEVPSell4,826$2.10$10,134.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Olivia Kyusuk BloomCFOSell3,379$2.10$7,095.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Daniel BradburyDirectorBuy142,776$1.75$249,858.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Melissa Kelly BehrsEVPSell12,310$2.13$26,220.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Olivia Kyusuk BloomCFOSell7,435$2.13$15,836.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2013John A ScarlettCEOBuy50,000$1.03$51,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Geron Corp. (NASDAQ:GERN)
DateHeadline
07/25/16 07:02 AMGERON CORP Files SEC form 8-K, Other Events -
07/24/16 03:55 PMTrading the Biotech News: Geron Corporation (NASDAQ:GERN), Medivation, Inc. (NASDAQ:MDVN) - The Voice Registrar
07/20/16 11:29 AMETF’s with exposure to Geron Corp. : July 20, 2016 -
07/20/16 07:04 AMGeron Corporation (NASDAQ:GERN) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/19/16 04:19 PMAnalysts Rating Overview: Bristol-Myers Squibb Company (NYSE:BMY) , Geron Corporation (NASDAQ:GERN) - Street Updates
07/19/16 04:19 PMShares of Geron Corporation (GERN) Drops by -2.21% - Trade Calls
07/15/16 07:10 AMGeron Corporation (GERN): Price Target and June Short Interest Disclosure - Trade Calls
07/14/16 04:21 PMGeron awarded three patents for telomerase inhibitor
07/14/16 04:21 PMGeron Corp (GERN) Receives Three U.S. Patents Related to Imetelstat
07/14/16 11:02 AMGeron (GERN) Gets Three Patents for Imetelstat in the U.S. -
07/14/16 07:33 AMStock Update (NASDAQ:GERN): Geron Corporation Announces Issuance of US Patents Related to Imetelstat - Smarter Analyst
07/13/16 07:03 AMGeron Corp (GERN) Receives Three U.S. Patents Related to Imetelstat - StreetInsider.com
07/13/16 06:53 AMGeron Announces Issuance of U.S. Patents Related to Imetelstat - [at noodls] - MENLO PARK, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the recent issuance of three U.S. patents related to the company's telomerase inhibitor, imetelstat. ...
07/12/16 08:36 AM2 Biotech Stocks News And Price Trends: Geron Corporation (NASDAQ:GERN), Array BioPharma Inc. (NASDAQ:ARRY) - The Voice Registrar
07/11/16 08:56 AMCompany Stock Focus for Geron Corporation (NASDAQ:GERN): Which Way Will Shares Head? - Press Telegraph
07/11/16 08:56 AMCompany Shares of Geron Corporation (NASDAQ:GERN) Drops by -1.09% - TheFounders Daily
07/10/16 08:38 AMNext Weeks Broker Price Targets For Geron Corporation (NASDAQ:GERN) - Fiscal Standard
07/08/16 11:59 AMIs Geron Corporation's Stock a Good Bargain After Falling 10% in June? - Geron takes another leg down.
07/06/16 08:53 AMStock Rating Watch and Earnings Insight for Geron Corporation (NASDAQ:GERN) - Press Telegraph
07/05/16 08:21 AMThe Waiting Game Takes Its Toll on Geron Corporation, With Shares Down 43% YTD -
07/04/16 03:52 PMGeron Corporation (NASDAQ:GERN) Broker Price Targets For The Coming Week - Fiscal Standard
07/04/16 03:52 PMShare Performance Recap for: Geron Corporation (NASDAQ:GERN) - Press Telegraph
07/01/16 04:13 PMGeron Corporation (NASDAQ:GERN) Company Rating and Target Watch - Telanagana Press
07/01/16 04:13 PMGeron: Announcing Imetelstat Patent Protection Through 2032 - Seeking Alpha
06/30/16 04:28 PMRecently Issued Stock Ratings For Geron Corporation (NASDAQ:GERN) - Fiscal Standard
06/28/16 09:10 PMGeron Corporation (GERN) Jumps 9.09% on June 28
06/22/16 08:50 AMEye Catching Stocks - Marathon Oil Corporation, (NYSE:MRO), Geron Corporation, (NASDAQ:GERN) - Hot Stocks Point
06/20/16 01:28 PMETF’s with exposure to Geron Corp. : June 20, 2016 -
06/19/16 03:53 PMGeron Corporation (NASDAQ:GERN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 03:46 PM9 Easy Ways to Lose Money in the Stock Market - Motley Fool
06/17/16 04:03 PMBiotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
06/16/16 08:31 AMAnalysts: Geron Corporation (NASDAQ:GERN) stock is worth $7.5 - iStreetWire
06/06/16 04:30 PMETF’s with exposure to Geron Corp. : June 6, 2016 -
06/06/16 04:02 PMWhich way Geron Corp. (NASDAQ:GERN) insiders are heading - iStreetWire
06/02/16 07:16 AMGeron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : June 2, 2016 -
06/02/16 07:16 AMGeron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : June 2, 2016 -
06/01/16 04:29 PMThe Outlook For Geron Corporation's Oncology Program - Seeking Alpha - Seeking AlphaThe Outlook For Geron Corporation's Oncology ProgramSeeking AlphaGeron Corporation (NASDAQ:GERN) made big splashes years ago by being the first company to receive approval to move a stem cell transplant therapy into clinical trials. Several years later, the company decided to focus its efforts on development of ...Recently Changed Price Targets On Geron Corporation (NASDAQ:GERN)Risers & Fallersall 4 news articles »
06/01/16 04:29 PMThe Outlook For Geron Corporation's Oncology Program - Seeking Alpha - Seeking AlphaThe Outlook For Geron Corporation's Oncology ProgramSeeking AlphaGeron Corporation (NASDAQ:GERN) made big splashes years ago by being the first company to receive approval to move a stem cell transplant therapy into clinical trials. Several years later, the company decided to focus its efforts on development of ...Recently Changed Price Targets On Geron Corporation (NASDAQ:GERN)Risers & Fallersall 4 news articles »
06/01/16 05:15 AMA Milestone Event In Geron's Imetelstat Phase II Study For Myelofibrosis Patients May Be Imminent - Geron (NASDAQ:GERN) CEO Dr. John (Skip) Scarlett recently provided investors ... The 4.7 mg dosage is the lowest dosage where the company predicts Telomerase inhibition would occur. Dr. Scarlett confirmed that the 9.4 mg dosage provided the best risk ...
05/30/16 12:39 AMGeron Co. (GERN) Earns Buy Rating from FBR & Co. - Let Me Know About This - Geron Co. (GERN) Earns Buy Rating from FBR & Co.Let Me Know About ThisGeron Co. (NASDAQ:GERN)'s stock had its “buy” rating reissued by investment analysts at FBR & Co. in a research report issued on Sunday. Geron (NASDAQ:GERN) traded up 1.42% during mid-day trading on Friday, reaching $2.85. The company had a ...
05/27/16 02:32 PMGeron Corporation (NASDAQ:GERN): Updated Analyst Ratings - iStreetWire - Geron Corporation (NASDAQ:GERN): Updated Analyst RatingsiStreetWireGeron Corporation (GERN) up 4.63 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 3 equity analysts who ...and more »
05/19/16 07:29 PMLatest Geron Corporation (NASDAQ:GERN) Target Price Suggests Stock Is Worth $7.5/Share - Street Register - News OracleLatest Geron Corporation (NASDAQ:GERN) Target Price Suggests Stock Is Worth $7.5/ShareStreet RegisterGeron Corporation (GERN) up 2.18 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 3 equity analysts who ...Geron Corporation (NASDAQ:GERN) Analyst ReviewRisers & Fallersall 9 news articles »
05/19/16 04:02 PMGERON CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 09:31 PMETF’s with exposure to Geron Corp. : May 19, 2016 -
05/16/16 10:09 AMGeron Corp. :GERN-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/15/16 02:37 PMNext Weeks Broker Price Targets For Geron Corporation (NASDAQ:GERN) - Share Trading News - Next Weeks Broker Price Targets For Geron Corporation (NASDAQ:GERN)Share Trading NewsGeron Corporation has a 50 day moving average of 3.02 and a 200 day moving average of 3.46. The stock's market capitalization is 419.65M, it has a 52-week low of 2.30 and a 52-week high of 5.30. The share price of the company (NASDAQ:GERN) was up ...and more »
05/08/16 10:15 AMCan Geron Shares Still Ultimately Double? -
05/06/16 12:06 PMEdited Transcript of GERN earnings conference call or presentation 5-May-16 8:30pm GMT -
05/06/16 07:18 AMGeron (GERN) Q1 Loss In-Line, Imetelstat Remains in Focus -
05/05/16 07:43 PMGeron's (GERN) CEO John Scarlett on Q1 2016 Results - Earnings Call Transcript - And welcome to the Geron First Quarter 2016 Earnings Conference Call ... I will now turn the call over to Chip to review current company events. Chip? Thanks, Olivia, good afternoon everyone and thanks for joining. I’ll begin with comments on the ...

Social

About Geron Corp.

Geron Corp. logoGeron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat exhibits relatively preferential inhibition of the clonal proliferation of malignant progenitor cells in nonclinical studies. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GERN
  • CUSIP: 37416310
Key Metrics:
  • Previous Close: $2.66
  • 50 Day Moving Average: $2.72
  • 200 Day Moving Average: $2.91
  • P/E Ratio: 883.33
  • P/E Growth: -2.08
  • Market Cap: $421.24M
  • Beta: 2.81
  • Current Year EPS Consensus Estimate: $-0.260 EPS
  • Next Year EPS Consensus Estimate: $-0.020 EPS
Additional Links:
Geron Corp. (NASDAQ:GERN) Chart for Monday, July, 25, 2016